FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Sep 28, 2026
Nanoviricides, Inc. (NNVC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $0 and a net loss of $8.2 million. Free cash flow was -$7.8 million.
Revenue
$0
Net income
$-8.22M
+13.2% vs prior year
Operating cash flow
$-7.70M
+9.2% vs prior year
Free cash flow
$-7.78M
+8.8% vs prior year
EPS
$-0.41
+34.9% vs prior year
Dividend per share
None
Shares outstanding
25.52M
+46.4% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NNVC (NYSE)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1379006
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| Operating income | -$8.3M | -$9.6M | -$8.5M | -$8.9M | -$8.1M |
| Net income | -$8.2M | -$9.5M | -$8.3M | -$8.6M | -$8.1M |
| Diluted EPS | -$0.41 | -$0.63 | -$0.70 | -$0.74 | -$0.70 |
| Operating cash flow | -$7.7M | -$8.5M | -$6.3M | -$5.7M | -$5.9M |
| Free cash flow | -$7.8M | -$8.5M | -$6.5M | -$5.8M | -$6.2M |
| Total assets | $9.9M | $8.8M | $12.8M | $16.9M | $23.5M |
| Total liabilities | $1.2M | $1.3M | $1.4M | $2.0M | — |
| Stockholders' equity | $8.7M | $7.5M | $11.5M | $14.9M | $23.1M |
| Cash and investments | $2.8M | $1.6M | $4.8M | $8.1M | $14.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 28, 2026 |
| 10-K | Annual report | Sep 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 30, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 20, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
May 20, 2026 | May 15, 2026 |
All 556 Nanoviricides, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.